Amarin Plc (NASDAQ: AMRN)
Amarin Plc Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Amarin Plc Company Info
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
News & Analysis
Why Amarin Stock Was Rocketing Higher on Wednesday
There was unambigously good news about the company's single commercialized medication.
Why Amarin Stock Skyrocketed Today
The biopharma company announced a big repurchase plan, along with strong preliminary Q4 results.
Why Amarin Stock Is Sinking Today
The drugmaker announced a major corporate reorganization and a new CEO.
Why Amarin Stock Tumbled This Week
Amarin's tussle with its largest stakeholder doesn't appear to be sitting well with shareholders.
Why Amarin Stock Was a Winner Today
The product most readily identified with the company will soon hit pharmacy shelves in Australia.
Why Amarin Stock Was Plunging This Week
Investors weren't happy with the company's decision to cease operations in a large country.
Why Investors Were Giving Amarin the Cold Shoulder Today
Although the company notched a revenue beat for its latest quarter, the bottom-line result fell short.
Why Amarin Stock Dipped This Week
The drugmaker's downward spiral continued.
Valuation
Podcast Episodes
Is Amarin's Fish Oil Pill on Track to Become a Blockbuster?
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
The Top Healthcare Stocks of 2018: Can They Continue in 2019?
These healthcare stocks crushed the S&P 500's return last year, but that doesn't guarantee they'll be top performers in 2019.
Biotech Stocks Made Big Progress Toward Preventing Heart Attacks in 2018
Key trials suggest doctors may change how they treat patients with cardiovascular disease.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.